The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...

Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Among 804 androgen receptor pathway inhibitor-experienced mCRPC patients, 459 patients (57.1%) received another androgen receptor pathway inhibitor as their index therapy and 192 (23.9%) received ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17 th and 21 st was host to the Poster presentation session. Dr. J. Connor ...

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...

As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage and grade. It exits in both secreted and membrane-associated forms, with ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...

Dr. Alexander Decruyenaere presented the poster Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Dr.

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...